| scholarly article | Q13442814 |
| P50 | author | Sakae Tanaka | Q39065998 |
| P2093 | author name string | Taku Saito | |
| Takumi Matsumoto | |||
| Jun Hirose | |||
| Yuho Kadono | |||
| Hisataka Yasuda | |||
| Tetsuro Yasui | |||
| Naoto Tokuyama | |||
| Hironari Masuda | |||
| Naohiro Izawa | |||
| Yasunori Omata | |||
| Toshinobu Ohmiya | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system | Q28283972 | ||
| Denosumab in postmenopausal women with low bone mineral density | Q28298728 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. | Q30627873 | ||
| Cell biology of the osteoclast | Q33700885 | ||
| Mechanisms of bone metastasis | Q33977526 | ||
| Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. | Q33995702 | ||
| Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis | Q34023772 | ||
| Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. | Q34107428 | ||
| Control of osteoblast function and regulation of bone mass | Q35128237 | ||
| Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts | Q35378487 | ||
| Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system | Q36891815 | ||
| Molecular mechanisms of bone resorption by the osteoclast | Q38286639 | ||
| Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 | ||
| The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis | Q44590934 | ||
| The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis | Q44590937 | ||
| A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 | ||
| Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD | Q58971166 | ||
| Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis | Q73490940 | ||
| Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice | Q80018761 | ||
| The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats | Q84890674 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| P304 | page(s) | 1-7 | |
| P577 | publication date | 2015-01-21 | |
| P1433 | published in | Bone reports | Q27726039 |
| P1476 | title | Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice | |
| P478 | volume | 2 |
| Q90115349 | Exosomes derived from Wharton's jelly of human umbilical cord mesenchymal stem cells reduce osteocyte apoptosis in glucocorticoid-induced osteonecrosis of the femoral head in rats via the miR-21-PTEN-AKT signalling pathway |
| Q88623230 | Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species |
| Q57168746 | The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease |
Search more.